Investor Presentation April-June 2021
Forward looking statements and non-IFRS measures
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. The terms 'Group' and 'Smith+Nephew' are used for convenience to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
Certain items included in 'trading results', such as trading profit, trading profit margin, tax rate on trading results, trading cash flow, trading profit to cash conversion ratio, EPSA, leverage ratio, and underlying growth are non-IFRS financial measures. The non-IFRS financial measures in this announcement are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS in our Fourth Quarter and Full Year 2020
Results announcement dated 18 February 2021, and our First Quarter 2021 trading report dated 29 April 2021. | 2 |
Our history
1856 | 1896 | 1914 | ||
Days after the outbreak of WW1, | ||||
Thomas James Smith | Horatio Nelson Smith | we received an order to provide | ||
1856 | opened a chemist shop in Hull, | entered into apartnership | surgical and field dressing | From50 |
UK and develops a new method | with his uncleforming | supplies to French | ||
Smith+Nephew | for refining cod liver oil | TJ Smith & Nephew | army within 5 months | To1200 |
established | During WW1, staff grew | |||
1986 | from 50 to 1,200 |
Key acquisitions of Richards Medical Company in Memphis, specialists in orthopaedic products and DYONICS, an arthroscopy specialists based in Andover
1995
Acquired
Acufex Microsurgical Inc,
making us a market leader in arthroscopic surgical devices
1953
We developed a special low-temperatureplaster for the Everest climbers on the 1953 expedition.
It enabled them to send back their camera films, sealed and airtight!. This same research led to the development of importantindustrial products
1937
We were listed on the London stock exchange
1928
We produced an
experimental bandage
ElastoplastTM
1999 | 2001 |
We were listed on the New York Stock | OXINIUM◊, a new material that |
Exchange and in 2001 became a constituent | improves performance and increases |
member of the UK FTSE-100 index | the service life of total joint |
replacement systems, firstintroduced |
2014 | 2013 | 2011 | |
Acquired Arthrocare Corp. | JOURNEY◊ II BCS sets a new standard inknee | PICO◊, the first pocket-sized,single-use | |
to expand our sports | implant performance,designed | system, revolutionizes the negative | |
medicine portfolio | to empower patients to return | pressure wound therapymarket | |
17,500+ | to an activelifestyle | ||
Over Today
2019 | 2020 | |
Expanding in technologies of the | We are proud of what we do | We exist to restore people's bodies and their self-belief |
future, investing inOrthopaedics, | and value our 17,500 employees | by using technologies to take the limits off living. |
Biologics and Digital Surgery. | who make thispossible | We call this purpose "LifeUnlimited" |
◊Trademark of Smith & Nephew, ©2020 Smith & Nephew
100
and growing
3
100
Smith+Nephew is a portfolio medical technology business that has been trading for over 160 years, and operates in more than 100 countries
FTSE 100 | Shares |
A constituent of the UK's | S+N has a progressive |
FTSE 100, with ADRs | dividend policy, and has |
traded on the New York | paid a dividend every |
Stock Exchange | year since 1937 |
$4.6bn | ~18,000 |
Annual sales in 2020 | We have around 18,000 |
were $4.6 billion | employees globally |
4
A portfolio medical technology business
ALLEVYN◊ LIFE | Advanced | Advanced |
Advanced Foam | ||
Wound Dressings | Wound Care | Wound Devices |
Collagenase | Advanced | |
SANTYL◊ Ointment | Wound | |
Enzymatic debrider | Bioactives | Knees |
ENT | $4.6bn | ||
Arthroscopic | Revenues | ||
COBLATION◊ | Enabling | (2020) | Hips |
Wand | Technologies |
REGENETEN◊ | Sports Medicine | ||
Bioinductive Implant | Joint Repair | Other Recon | Trauma |
PICO◊
Negative Pressure
Wound Therapy
JOURNEY◊ II BCS
Bi-Cruciate
Stabilised
Knee System
OR3O◊
Dual Mobility
EVOS◊ SMALL Plating System
CORI◊
Surgical
System
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Smith & Nephew plc published this content on 11 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2021 10:31:03 UTC.